Market news

Amneal Pharmaceuticals (AMRX) has an average rating of buy and mean price target of $22, according t

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

Amneal Pharmaceuticals (AMRX) said Friday that the US Food and Drug Administration approved its lanr

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch imme

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...

On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals and Caterpillar emerge as high-efficiency stocks poised for stronger returns.

Amneal Pharmaceuticals stock has delivered very strong gains over the last few years, yet the broad valuation checks suggest it no longer looks like a clear bargain at around US$18.19. Over the past 3 years, Amneal Pharmaceuticals has returned about 3.5x. This puts recent price strength front and centre for anyone assessing the current valuation. The key support for the share price can come from expectations that Amneal Pharmaceuticals keeps converting revenue into cash efficiently. Any...

AMRX's Kashiv deal creates an integrated biosimilars platform, but integration, regulatory execution and product uptake remain key.

Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Amneal Pharmaceuticals (AMRX) has a favorable setup with near-term growth from several biosimilar/ge

Amneal Pharmaceuticals (AMRX) has an average rating of overweight and mean price target of $20.75, a

Amneal tops second-quarter earnings and revenue estimates and lifts its 2026 outlook.

After a very strong three year run for Amneal Pharmaceuticals, the stock no longer looks obviously cheap, and the latest valuation checks suggest investors should be careful about assuming further easy gains from here. Amneal Pharmaceuticals has delivered a very large 345.7% return over the past three years, which sets a high bar for future returns to justify the current price. Expectations around Amneal Pharmaceuticals’ ability to sustain cash generation and manage its balance sheet can...

Detailed price information for Amneal Pharmaceuticals Inc (AMRX-Q) from The Globe and Mail including charting and trades.

Amneal: Q2 Earnings Snapshot

Amneal Pharmaceuticals (AMRX) reported Q2 adjusted earnings Thursday of $0.30 per diluted share, up

Amneal Pharmaceuticals (NASDAQ:AMRX) reported second-quarter 2026 revenue of $796 million, up 10% from a year earlier, as growth in its affordable medicines and specialty businesses offset a decline at its AvKARE distribution unit. The company raised its full-year revenue, adjusted EBITDA and adjust

Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amneal (AMRX) delivered earnings and revenue surprises of +25.00% and +3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on year to $796.2 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 30.3% above analysts’ consensus estimates.

Moby summary of Amneal Pharmaceuticals, Inc.'s Q2 2026 earnings call

Amneal delivers seventh consecutive year of growth with revenue up 10% to $796 million, raises full-year guidance, and advances biosimilar strategy with Kashiv acquisition.